- •Fingolimod associated macular oedema (FAME) is a rare but recognised complication.
- •The real-world FAME incidence is consistent with fingolimod registration studies.
- •Most cases present within the first four months but a delayed onset is possible.
- •Newer optical coherence tomography devices may better detect subtle FAME.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Multiple Sclerosis and Related Disorders
Pharm N. Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MShttps://www.novartis.com/news/media-releases/novartis-data-aan-show-gilenya-first-and-only-disease-modifying-therapy-proven-superiority-versus-glatiramer-acetate-relapsing-remitting-ms20192019.[cited 2019 18 August].
- Fingolimod: therapeutic mechanisms and ocular adverse effects.Eye (Lond). 2017; 31: 232-240
- Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity.J. Biol. Chem. 2006; 281: 29190-29200
- Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.Ophthalmology. 2013; 120: 1432-1439
- Fingolimod and macular edema: pathophysiology, diagnosis, and management.Neurol. Clin. Pract. 2014; 4: 402-409
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet. 2016; 387: 1075-1084
- Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 402-415
- A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.N. Engl. J. Med. 2010; 362: 387-401
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Neurol. 2014; 13: 545-556
- FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study.Nephrol. Dial Transplant. 2011; 26: 3802-3805
- FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.Am. J. Transplant. 2006; 6: 1848-1857
- FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia.Am. J. Transplant. 2006; 6: 2912-2921
- Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.Transplantation. 2006; 82: 1689-1697
- FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study.Transplantation. 2007; 84: 885-892
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.J. Neurol. Neurosurg. Psychiatry. 2016; 87: 468-475
- Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.Neurology. 2015; 84: 1582-1591
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.Lancet Neurol. 2011; 10: 520-529
- Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.BMC Neurol. 2014; 14: 21
- A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.Mult Scler. 2012; 18: 1269-1277
Provider: King's College Hospital NHS Foundation Trusthttps://www.cqc.org.uk/provider/RJZ/reports2019.[cited 2020 17 March]. Available from: https://www.cqc.org.uk/provider/RJZ/reports.
NICE. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosishttps://www.nice.org.uk/guidance/ta2542012.[2019 18 August].
Council M.R. Is study research?http://www.hra-decisiontools.org.uk/research/ [2019 18 August].
- Drug-induced macular edema.Drugs. 2013; 73: 789-802
- Cystoid macular edema and visual loss as sequelae to interferon alpha treatment of systemic hepatitis C.Indian J Ophthalmol. 2010; 58: 147-148
- Microcystic macular oedema in multiple sclerosis is associated with disease severity.Brain. 2012; 135: 1786-1793
- Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.J. Neurol. 2014; 261: 267-276
- Early tolerability and safety of fingolimod in clinical practice.J. Neurol. Sci. 2012; 323: 167-172
- Safety and Tolerability of Fingolimod in Latin American Patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study.Adv. Ther. 2015; 32: 626-635
- Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.Neurol. Sci. 2017; 38: 53-59
- Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis.Int. Ophthalmol. 2018;
- Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.CNS Drugs. 2014; 28: 817-824
- The effectiveness of fingolimod in a Portuguese real-world population.Mult. Scler Relat. Disord. 2016; 6: 41-48
- Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): an observational study in the UK.Mult. Scler. J. Exp. Transl. Clin. 2018; 42055217318801638
- Cystoid macular edema associated with fingolimod use for multiple sclerosis.JAMA Ophthalmol. 2013; 131: 103-107
- Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.JAMA Ophthalmol. 2013; 131: 802-804